Avacta to Host Therapeutics Division Science Day on 23rd February 2023

Science Day to include presentation of the data emerging from the phase 1a clinical trial of AVA6000

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will host a Science Day for City analysts and fund managers on 23rd February 2023 to discuss recent progress within the Company’s Therapeutics Division and hear from selected key opinion leaders in the field of oncology.

The event will include an update on the ongoing preclinical programmes as well as on progress in the ALS-6000-101 phase 1a clinical trial of AVA6000, Avacta’s lead pre|CISIONTM tumour targeted chemotherapeutic, a modified form of the chemotherapy doxorubicin.

The Company will update the Market on progress in this study in early January 2023, in advance of the Science Day.

A recording of the presentations will be available after the event on Avacta’s website www.avacta.com.